Pre-clinical study of 21 approved drugs in the mdx mouse. 2011

Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
CGMC, CNRS-UMR 5534, Université Claude Bernard Lyon-1, 69622 Villeurbanne, France. maite.carre-pierrat@univ-lyon1.fr

Duchenne muscular dystrophy, a genetic disease caused by the absence of functional dystrophin, remains without adequate treatment. Although great hopes are attached to gene and cell therapies, identification of active small molecules remains a valid option for new treatments. We have studied the effect of 20 approved pharmaceutical compounds on the muscles of dystrophin-deficient mdx5Cv mice. These compounds were selected as the result of a prior screen of 800 approved molecules on a dystrophin mutant of the invertebrate animal model Cænorhabditis elegans. Drugs were administered to the mice through maternal feeding since 2weeks of life and mixed in their food after the 3rd week of life. The effects of the drugs on mice were evaluated both at 6weeks and 16weeks. Each drug was tested at two concentrations. Prednisone was added to the molecule list as a positive control. To investigate treatment efficiency, more than 30 histological, biochemical and functional parameters were recorded. This extensive study reveals that tricyclics (Imipramine and Amitriptyline) are beneficial to the fast muscles of mdx mice. It also highlights a great variability of responses according to time, muscles and assays.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016189 Dystrophin A muscle protein localized in surface membranes which is the product of the Duchenne/Becker muscular dystrophy gene. Individuals with Duchenne muscular dystrophy usually lack dystrophin completely while those with Becker muscular dystrophy have dystrophin of an altered size. It shares features with other cytoskeletal proteins such as SPECTRIN and alpha-actinin but the precise function of dystrophin is not clear. One possible role might be to preserve the integrity and alignment of the plasma membrane to the myofibrils during muscle contraction and relaxation. MW 400 kDa.

Related Publications

Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
June 2000, Neuromuscular disorders : NMD,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
July 1952, Hospital management,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
August 1952, Hospital management,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
January 2012, Neuromuscular disorders : NMD,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
June 1952, Hospital management,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
May 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
February 2023, International journal of molecular sciences,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
March 1973, Minerva medica,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
May 2022, British journal of clinical pharmacology,
Maïté Carre-Pierrat, and Aude Lafoux, and Guillaume Tanniou, and Lucie Chambonnier, and Alexandra Divet, and Francoise Fougerousse, and Corinne Huchet-Cadiou, and Laurent Ségalat
December 2017, The Journal of physiology,
Copied contents to your clipboard!